HeartBeam, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:03 pm EST
Share
HeartBeam, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 3.47 million compared to USD 3.58 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.44 a year ago.
For the nine months, net loss was USD 10.76 million compared to USD 9.25 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 1.14 a year ago.
HeartBeam, Inc. is a cardiac technology company. The Company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The Company is engaged in the development of its proprietary and patented Vector Electrocardiography (VECG) technology platform. Its VECG is capable of developing three-dimensional vector images of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It has two patented products in development, such as HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack. HeartBeam AIMIGo is a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.